fbpx
News
June 13, 2017

Louisiana Federal Jury Rules in Favor of Defendant in Xarelto Trial

“It’s not looking good for the Xarelto plaintiffs’ bar,” writes the National Law Journal. Yesterday, “a jury came out with a defensive verdict in the second trial over the [Xarelto] blood thinner. That’s about a month after Johnson & Johnson and Bayer won the first bellwether trial over Xarelto.”

In the first trial, jurors deliberated for less than two hours before rendering their verdict on May 3. This time, the jury deliberated for about three hours.

The Institute for Legal Reform has highlighted the dangers associated with trial lawyer drug advertising, similar to the ads used in Xarelto litigation, which solicit potential plaintiffs. These ads can scare patients out of taking lifesaving medications. 

Cookie Notice

By clicking “I Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

Cookie Notice

By clicking “I Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Review Settings